Ablynx NV (XBRU:ABLXS) Total Equity : €179.86 Mil (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV Total Equity?

Ablynx NV's total equity for the quarter that ended in Dec. 2017 was €179.86 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Ablynx NV Total Equity Historical Data

The historical data trend for Ablynx NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Total Equity Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Equity

Get a 7-Day Free Trial

46.17

75.47

27.91

103.06

179.86

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
Total Equity	Get a 7-Day Free Trial															27.91	125.53	103.06	80.43	179.86

Ablynx NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Ablynx NV's Total Equity for the fiscal year that ended in Dec. 2017 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2017 )	-	Total Liabilities(Q: Dec. 2017 )
	=	389.848	-	209.992
	=	179.86

Ablynx NV's Total Equity for the quarter that ended in Dec. 2017 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2017 )	-	Total Liabilities(Q: Dec. 2017 )
	=	389.848	-	209.992
	=	179.86

Ablynx NV Total Equity Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines